海创药业：预计2025年全年归属净利润亏损1.25亿元至1.5亿元

Core Viewpoint - The company is expected to report a net loss of 125 million to 150 million yuan for the year 2025 due to various factors affecting its revenue and expenses [1] Group 1: Performance Forecast - The company anticipates a net profit loss of 125 million to 150 million yuan for the full year of 2025 [1] - The expected operating revenue for 2025 is projected to be between 19 million and 22 million yuan, primarily due to limited sales from its first Class 1 new drug, HC-1119, and the impact of its inclusion in the National Medical Insurance Drug List [1] - The company plans to reduce R&D expenses to between 105 million and 125 million yuan in 2025, a decrease of 49.03 million to 69.03 million yuan compared to the previous year [1] Group 2: Q3 2025 Financial Results - For the first three quarters of 2025, the company's main revenue reached 23.35 million yuan, a significant increase of 21,180.28% year-on-year [2] - The net profit attributable to shareholders for the same period was -99.15 million yuan, reflecting a year-on-year increase of 35.65% [2] - The company reported a gross margin of 99.57% for Q3 2025, with a single-quarter main revenue of 10.18 million yuan [2]